Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients
Transfusion Medicine and Hemotherapy · 16.02.2026 · 53 (3) · 134-144
DOI: 10.1159/000550469 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion Medicine and Hemotherapy, online erschienen am 16.02.2026. Verfasst von Robert Zeiser und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University Medical Center, Freiburg im Breisgau, Germ…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Acute graft-versus-host disease (aGvHD) is a potentially life-threatening complication that can occur following allogeneic haematopoietic stem cell transplantation. Although corticosteroids remain the standard first-line therapy, a considerable number of patients fail to respond adequately, leading to significant morbidity.
Methods
Mesenchymal stromal cells (MSCs) are being investigated as a therapeutic option in this setting due to their immunomodulating and tissue-regenerative properties. Two ongoing clinical trials – IDUNN (NCT04629833) and BALDER (NCT06075706) – are assessing the role of the innovative product MSC-FFM/MC0518 in managing steroid-refractory aGvHD (SR-aGvHD). In parallel, a dedicated surveillance programme is collecting long-term efficacy and safety data to inform clinical use beyond the controlled trial environment.
Conclusion
The IDUNN and BALDER trials will deliver definitive evidence on the efficacy and safety of MC0518 in SR-aGvHD and may shape future therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University Medical Center, Freiburg im Breisgau, Germany.
- Faculty of Medicine, Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt am Main, Germany.
- German Red Cross Blood Service BaWüHe, Institute Frankfurt, Frankfurt am Main, Germany.
- medac GmbH, Wedel, Germany.
- Department of Pediatrics, Division of Stem Cell Transplantation and Immunology, Goethe University Frankfurt, Frankfurt am Main, Germany.
Zitieren
APA
Zeiser, R., Bönig, H., Osswald, E., Pichlmeier, U., Möller, A. K., Tribanek, M., Lazarou-Wild, M., von der Weth, R., Pfeffermann, L. M., & Bader, P. (2026). Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients. Transfusion Medicine and Hemotherapy, 53(3), 134-144. https://doi.org/10.1159/000550469
Vancouver
Zeiser R, Bönig H, Osswald E, Pichlmeier U, Möller AK, Tribanek M, et al. Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients. Transfusion Medicine and Hemotherapy. 2026;53(3):134-144. doi:10.1159/000550469
BibTeX
@article{Zeiser2026,
author = {Zeiser, Robert and Bönig, Halvard and Osswald, Elena and Pichlmeier, Uwe and Möller, Ann-Kristin and Tribanek, Michael and Lazarou-Wild, Maria and von der Weth, Renate and Pfeffermann, Lisa-Marie and Bader, Peter},
title = {Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients},
journal = {Transfusion Medicine and Hemotherapy},
year = {2026},
volume = {53},
number = {3},
pages = {134--144},
doi = {10.1159/000550469}
}
EUVIMED